Bellicum Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Bellicum Pharmaceuticals Inc.
Fidelity Select Biotechnology Portfolio
1,342,278
3.1%
0
0.11%
07/31/2018
Vanguard Total Stock Market Index Fund
1,032,463
2.38%
0
0%
07/31/2018
JPMorgan Small Cap Growth Fund
1,022,374
2.36%
81,876
0.28%
07/31/2018
JPMorgan Funds - Global Healthcare Fund
1,013,639
2.34%
0
0.25%
05/31/2018
iShares Russell 2000 ETF
833,829
1.92%
-444
0.01%
09/06/2018
Vanguard Extended Market Index Fund
573,954
1.32%
0
0.01%
07/31/2018
ARK Genomic Revolution Multi Sector ETF
520,468
1.2%
2,906
1.22%
09/05/2018
iShares Nasdaq Biotechnology ETF
502,737
1.15%
-6,573
0.04%
09/06/2018
iShares Russell 2000 Growth ETF
275,825
0.64%
0
0.02%
09/06/2018
Fidelity Advisor Biotechnology Fund
265,365
0.61%
-243,912
0.07%
07/31/2018
| Address |
Life Science Plaza
Houston Texas 77030
United States
|
|
Employees
|
- |
| Website |
http://www.bellicum.com |
| Updated |
07/08/2019 |
| Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. |
